NuVasive Inc NUVA
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
NuVasive Inc is a medical device company focused on minimally invasive surgical products and integrated solutions for spine surgery. The firm's spine surgery products contribute to the majority of revenue. Its key offering is the maximum access surgery minimally disruptive surgical platform, which minimizes soft-tissue disruption and contact with critical nerves and maximizes visualization during spine fusion surgery. NuVasive also develops biologics used to aid in the spinal fusion or bone-healing processes, such as a collagen-based synthetic bone substitute and synthetic bone-graft material. NuVasive generates the majority of its revenue in the United States.
San Diego, CA, 92121